Semaglutide vs Tirzepatide: Which Works Better?

If you are choosing between semaglutide and tirzepatide — or wondering whether the one you are on is the "best" option — you are asking the most useful question in this whole drug class. These two medicines dominate GLP-1 weight management, and for the first time there is a direct, head-to-head randomized trial that pits them against each other. The short version: tirzepatide produced more weight loss in that trial. The honest version, which is what this guide is about, is that the gap is real but not enormous, the side-effect profiles differ in ways that matter to real people, and "better on average" is not the same as "better for you."

A grounding fact first. Semaglutide is a single-receptor drug — it activates the GLP-1 receptor. It is sold as Wegovy (for chronic weight management), Ozempic (for type 2 diabetes), and Rybelsus/oral Wegovy (the pill form). Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP receptor — and is sold as Zepbound (weight management) and Mounjaro (diabetes). That one mechanistic difference is the headline of the whole comparison: one hormone pathway versus two. (Because semaglutide wears several brand names, it helps to first sort out Ozempic vs Wegovy — same drug, different label.)

The head-to-head trial: tirzepatide came out ahead

For years, comparisons between these two drugs were indirect — you lined up the semaglutide trials next to the tirzepatide trials and squinted. That is unreliable, because the trial populations and designs differ. In 2025 that changed: SURMOUNT-5, published in the New England Journal of Medicine, was a direct, randomized, head-to-head trial comparing the two at the trial's maximum tolerated regimens — tirzepatide 10/15 mg and semaglutide 1.7/2.4 mg weekly — in adults with obesity (without diabetes)¹.

The result: at 72 weeks, participants on tirzepatide lost about 20.2% of body weight, versus about 13.7% on semaglutide¹. That is a meaningful difference — roughly a 6.5-percentage-point edge for tirzepatide — and it is the strongest single piece of evidence in this comparison precisely because the medicines were compared in randomized groups within the same trial. The study did not test combining them or compare tirzepatide with the newer 7.2 mg Wegovy dose.

But read that result honestly. Both groups lost a great deal of weight; semaglutide's ~13.7% is itself a strong result that would have been considered remarkable a decade ago. Tirzepatide won, but it did not make semaglutide look weak. And SURMOUNT-5 enrolled people without diabetes — weight loss tends to be somewhat smaller in people with type 2 diabetes for both drugs, so these exact numbers do not transfer perfectly to every patient.

Why the indirect numbers line up with this

The head-to-head result is consistent with what the individual trials showed. In STEP 1, once-weekly semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks versus placebo in adults with obesity². In SURMOUNT-1, tirzepatide produced up to about 20.9% weight loss at its highest dose over 72 weeks³. Those separate trials hinted at tirzepatide's edge; SURMOUNT-5 confirmed it directly rather than by cross-trial guesswork.

A network meta-analysis comparing GLP-1 medicines for obesity reached the same broad conclusion — tirzepatide sits at the top of the efficacy ranking for weight loss among the agents studied⁴. The pattern is consistent enough that "tirzepatide produced more weight loss than the semaglutide injection regimens tested" is a fair, evidence-backed statement. That weight-loss edge also spills into a related indication: tirzepatide (as Zepbound) is now FDA-approved to treat obstructive sleep apnea, while semaglutide is not — we unpack that distinction in does Wegovy or Ozempic help sleep apnea?.

Side effects: similar categories, real differences in degree

Both drugs share the same dominant side-effect story: gastrointestinal. Nausea, diarrhea, constipation, and vomiting are the most common adverse events for both, they cluster around dose increases, and they tend to ease as the body adjusts. A systematic review and meta-analysis comparing semaglutide and tirzepatide against placebo in people with obesity found that both significantly raise GI adverse events versus placebo, with nausea and diarrhea leading the list for each⁵.

The practical differences are in degree and discontinuation. In SURMOUNT-5, the overall side-effect profiles were broadly similar and consistent with the class, and GI events were the most common reason people struggled — but most were mild to moderate and most people stayed on treatment¹. The takeaway is not "one is gentle and one is harsh." Both can cause substantial gastrointestinal symptoms. The trial does not establish that titration speed matters more than the choice of medicine for an individual. Ask the prescriber how to handle symptoms within the product-specific escalation plan; our semaglutide dosing and side effects guide explains that discussion.

Both product labels carry a boxed warning about thyroid C-cell tumors based on rodent findings and warnings about pancreatitis and gallbladder disease.^11,12 Shared warning categories do not prove identical risks. The semaglutide-specific vision signal discussed elsewhere should not be treated as an established effect of every medicine in the class. (We cover the semaglutide-specific versions in semaglutide and pancreatitis and semaglutide, gallbladder and kidneys.)

Cardiovascular outcomes: match the product and population

SELECT established cardiovascular benefit with semaglutide in adults with established cardiovascular disease and overweight or obesity without diabetes. SUSTAIN-6 studied a different population with type 2 diabetes.^6,7 These are distinct bodies of evidence, not a reason to assume every semaglutide formulation has every indication.

Tirzepatide's outcomes trial is no longer merely pending. SURPASS-CVOT compared tirzepatide with dulaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease; tirzepatide met the noninferiority criterion for major cardiovascular events.¹⁰ That active-comparator result should not be described as a placebo-controlled superiority result or automatically transferred to adults with obesity without diabetes.

The current Mounjaro label, updated August 2026, includes major cardiovascular event reduction in adults with type 2 diabetes at high risk. Zepbound, although the same active ingredient, has its own weight-management and obstructive sleep apnea indications rather than that Mounjaro indication.^9,12 Wegovy's cardiovascular indication likewise has its own eligible population.¹¹

A benefit-risk comparison needs the condition being treated, dose, formulation and actual label attached. Older network analyses do not substitute for newer trial results or current prescribing information.⁸ These cardiovascular findings concern distinct trial populations and approved products.

So which is "better"?

Honestly: it depends on the goal.

• •For weight loss at the tested regimens, SURMOUNT-5 favored tirzepatide (20.2% vs 13.7%); it did not test the current 7.2 mg Wegovy dose.^1,11
• •For cardiovascular risk reduction, match the approved product and population: Wegovy has obesity/overweight and established-CVD criteria; Mounjaro has a high-risk type 2 diabetes indication.^9,11
• •For tolerability, both commonly cause gastrointestinal effects. Different doses, titration and individual response matter; cross-trial rates cannot establish which one you will tolerate better.⁵
• •For practical access, cost, insurance coverage, and supply often decide it more than efficacy. Cash prices for both, pills and pens, are side by side in the cheapest GLP-1 without insurance, and Wegovy vs Zepbound compares the two brands dose by dose. The drug you can actually get and afford, and tolerate well enough to stay on, beats the theoretically "stronger" one you quit.

Do not try to obtain both drugs’ effects by taking them together: semaglutide and tirzepatide coadministration is not recommended by the product labels.^11,12

Neither is a casual choice — both are prescription drugs with a boxed warning and a real side-effect profile, started and monitored under a clinician. If you are switching from a different drug, our guide on switching from Zepbound to Wegovy walks through how that transition is handled in practice. And tirzepatide's "two pathways beat one" logic now has a semaglutide-side rival on the horizon — the not-yet-approved combination CagriSema, which adds an amylin drug on top of semaglutide; we break that down in CagriSema vs Wegovy. Cost usually settles the argument in practice, and a few programs make the gap visible rather than leaving you to guess: Effecty prints its brand-name Ozempic, Wegovy and Zepbound cash prices next to its compounded ones, Sprout Health prices compounded semaglutide below compounded tirzepatide, at one rate for every dose, and Telos Rx prices both by plan length rather than by dose. It also cuts the other way: at some sellers the two molecules are not even sold on the same terms. Vyvron sells semaglutide as a recurring plan and offers tirzepatide only as a prepaid block, with no monthly option at any price — so if tirzepatide is what the trial data pushed you toward, the cheapest way in there is $790 up front. A smaller number treat the choice as reversible rather than final: one program sells tirzepatide as needle-free drops and lets a clinician swap your molecule under the plan you already hold, which matters if you start on one and want the other without restarting somewhere else. Sometimes the difference between the two molecules is not in the price but in what the seller is willing to promise about it: one seller states that its tirzepatide price does not move with your dose, and prints no equivalent statement — in either direction — on its semaglutide plan, so the same shopper gets a straight answer about titration cost on one molecule and silence on the other. That is worth checking before you decide, because your maintenance dose is where a GLP-1 bill is actually settled. Bear in mind that the sublingual route is the least-studied way to take either drug — the head-to-head numbers above come from injections, not drops. And whichever you land on, the broader evidence picture is laid out in our semaglutide evidence guide, with provider options compared in our best semaglutide providers roundup — or, sorted by the tirzepatide figure specifically, our best tirzepatide providers page.